

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 October 2021 (21.10.2021)



(10) International Publication Number
WO 2021/212083 A3

- (51) **International Patent Classification:**
A61K 48/00 (2006.01) *A61P 37/02* (2006.01)
A61K 38/00 (2006.01)
- (21) **International Application Number:**
PCT/US2021/027838
- (22) **International Filing Date:**
16 April 2021 (16.04.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/011,742 17 April 2020 (17.04.2020) US
63/150,451 17 February 2021 (17.02.2021) US
- (71) **Applicant: THE BOARD OF TRUSTEES OF THE LE-
LAND STANFORD JUNIOR UNIVERSITY [US/US];**
Office of The General Counsel, Bldg 170, 3rd Flr, Main
Quad, P.O. Box 20386, Stanford, CA 94305-2038 (US).
- (72) **Inventors: GARCIA, Kenan, Christopher;** c/o Office
of Technology Licensing, 3000 El Camino Real, Building
Five, Third Floor, Palo Alto, CA 94306 (US). **GLASS-
MAN, Caleb, R.;** c/o Office of Technology Licensing, 3000
El Camino Real, Building Five, Third Floor, Palo Alto, CA
94306 (US).
- (74) **Agent: DANG, David, V. et al.;** Mintz Levin Cohn Fer-
ris Glovsky and Popeo, P.C., One Financial Center, Boston,
MA 02111 (US).
- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) **Title:** ENGINEERED IL-12 AND IL-23 POLYPEPTIDES AND USES THEREOF




FIG. 2G

(57) **Abstract:** The present disclosure relates generally to compositions and methods for modulating signal transduction mediated by interleukin-12 and interleukin-23. In particular, the disclosure provides novel variants of interleukin-12 subunit p40 with reduced binding affinity to IL-12R β 1. Also provided are compositions and methods useful for producing such IL-12p40 polypeptide variants, as well as methods for modulating IL-12p40-mediated signaling, and/or for the treatment of conditions associated with perturbations of signal transduction mediated by IL-12p40.

[Continued on next page]

WO 2021/212083 A3

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

25 November 2021 (25.11.2021)